For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Livagen (Lys-Glu-Asp-Ala, KEDA) is a Khavinson tetrapeptide designed from liver tissue peptide analysis. Its distinctive position in the family comes from two mechanistically specific findings: the 2002 Khavinson/Lezhava indexed study demonstrated chromatin deheterochromatinization in human lymphocytes from elderly donors (activation of ribosomal genes and decondensation of pericentromeric heterochromatin), and the 2003 Kost et al. study from the Mental Health Research Center in Moscow (an external institution) found that Livagen inhibits enkephalin-degrading enzymes in human serum with an IC50 of 20 micromolar, outperforming known peptidase inhibitors puromycin, leupeptin, and D-PAM. Neither study constitutes a clinical trial. No human efficacy data in any disease indication has been published.
Livagen is a research compound with no FDA or EMA approval, no completed human clinical trials, and no published human efficacy data for any indication. The compound is entirely at the preclinical and in vitro stage. Unlike Pancragen (which has an indexed n=33 human DM2 study) or Vesugen (which has uncontrolled observational cardiovascular data), Livagen has no published data in human patients with any disease.
What Livagen does have is two mechanistically specific indexed findings using human biological material in vitro: the 2002 chromatin activation study using lymphocytes from elderly human donors, and the 2003 enkephalin enzyme inhibition study using human serum. These are in vitro experiments, not clinical trials. The distinction is critical.
The enkephalin-degrading enzyme inhibition finding is unusually specific and was conducted at the Mental Health Research Center, Russian Academy of Medical Sciences, Moscow, an institution independent of the St. Petersburg Institute. IC50 of 20 micromolar for Livagen versus 500 micromolar for Epitalon and versus established inhibitors puromycin, leupeptin, and D-PAM. No interaction with mu or delta opioid receptors was observed, meaning Livagen does not act as an opioid agonist. The physiological significance of enkephalinase inhibition in vivo is not established by the in vitro data.
All primary Livagen research originates from the St. Petersburg Institute of Bioregulation and Gerontology and closely affiliated groups. The one exception is the 2003 Kost et al. enkephalin paper from Moscow, which is the only clearly independent external institutional validation in the Livagen literature.
Livagen (also designated KEDA in some publications) is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala, developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is positioned as the liver and gastrointestinal tract-targeted member of the Khavinson bioregulator family, derived from amino acid analysis of peptide extracts from liver tissue.
The sequence places Livagen in a structural relationship to Vesugen (Lys-Glu-Asp) and Pancragen (Lys-Glu-Asp-Trp): all three share the KED core tripeptide, with Livagen extending it by C-terminal alanine and Pancragen extending it by C-terminal tryptophan. The tissue specificity claimed for these compounds, liver for Livagen and pancreas for Pancragen, is proposed to be conferred by the C-terminal residue. Whether alanine specifically targets liver tissue over vascular or pancreatic tissue has not been systematically demonstrated in vivo using properly controlled tissue distribution studies.
Livagen's research focus spans three distinct biological domains that have been investigated in separate bodies of work: (1) chromatin remodeling in aging immune cells (the lymphocyte deheterochromatinization studies, which are the most directly human-relevant findings); (2) hepatoprotective and gastrointestinal enzyme effects (the rat and cell culture liver studies); and (3) enkephalin-degrading enzyme inhibition in human serum (the most mechanistically specific finding with the most institutional independence).
Unlike Cardiogen, Pancragen, and Vesugen, Livagen does not appear to be sold in oral capsule form as a commercial supplement through the St. Petersburg Institute's distribution channels. It is available as a research peptide from multiple vendors at standard bioregulator pricing but lacks the commercial therapeutic positioning given to other family members. This may reflect the Institute's own assessment that the liver/GI findings do not yet justify supplement promotion.
Livagen operates through at least two mechanistically distinct pathways that are independently characterized in the indexed literature: chromatin remodeling via heterochromatin deheterochromatinization, and enkephalin-degrading enzyme inhibition.
The chromatin mechanism follows the same framework proposed for other Khavinson bioregulators. In the 2002 Khavinson/Lezhava study (Bulletin of Experimental Biology and Medicine), lymphocytes isolated from elderly human donors were treated with Livagen in vitro. The findings included: activation of ribosomal genes; decondensation of pericentromeric structural heterochromatin; and release of genes repressed due to age-related condensation of euchromatic regions. The overall conclusion was that Livagen causes de-heterochromatinization of chromatin in aging human lymphocytes, reversing a molecular feature associated with cellular aging.
Pericentromeric structural heterochromatin is particularly relevant because it contains repetitive sequences and satellite DNA that condense progressively with aging, producing a characteristic pattern of gene silencing. Livagen decondensed chromosome 1 pericentromeric heterochromatin in these experiments (along with Epitalon and Prostamax in companion studies). This distinguishes Livagen from Vilon, which in similar experimental systems did not affect pericentromeric structural heterochromatin but did affect facultative heterochromatin. The differential chromatin-targeting profile of these related peptides is consistent with sequence-specific binding rather than nonspecific DNA disruption.
The structural basis for chromatin binding follows the same logic as for other Khavinson bioregulators: the charged KEDA sequence (lysine positive, glutamic acid and aspartic acid negative) enables minor groove docking through electrostatic complementarity with DNA and histone proteins. Alanine contributes hydrophobic stability to the interaction. Molecular docking studies supporting this mechanism for the KEDA motif have been cited in Khavinson review literature but the specific published docking analysis for Livagen specifically has not been separately identified.
The enkephalin enzyme inhibition mechanism is entirely distinct from the chromatin model and was characterized by an independent institution. Enkephalins are endogenous opioid pentapeptides that produce analgesic, cardioprotective, and immunomodulatory effects through mu and delta opioid receptors. Their biological half-life is very short because they are rapidly degraded by serine proteases and metallopeptidases in blood (enkephalinases/neutral endopeptidases). Inhibiting these enzymes prolongs enkephalin activity without requiring receptor agonism.
The 2003 Kost et al. study from the Mental Health Research Center, Moscow (Biology Bulletin of the Russian Academy of Sciences) tested Livagen and Epitalon in vitro against human serum enkephalinase activity, measuring the rate of tritium-labeled leucine-enkephalin hydrolysis. Livagen inhibited enkephalin-degrading enzymes with an IC50 of 20 micromolar. Epitalon's IC50 was 500 micromolar. Livagen outperformed the established inhibitors puromycin, leupeptin, and D-PAM. Neither peptide interacted with mu or delta opioid receptors in a radioreceptor assay using rat brain membrane fractions.
An IC50 of 20 micromolar is a meaningful potency in an enzyme inhibition context, particularly for a peptide of this size. The comparison to established inhibitors is quantitatively impressive. The limitation is that this is an in vitro serum assay. Whether Livagen achieves 20 micromolar concentrations in blood at pharmacologically relevant doses in vivo is unknown; no human PK data exist. The in vivo significance of enkephalin protection would depend on achieving sufficient tissue concentrations to produce measurable increases in endogenous enkephalin levels.
For the gastrointestinal effects, the 2005 Timofeeva et al. study (Advances in Gerontology) documented that Livagen is resistant to hydrolysis by small intestinal peptidases in vitro, and that oral Livagen in aged rats increased digestive enzyme activity toward levels seen in young animals, while reducing activity in young animals. This bidirectional, age-dependent normalization is consistent with the general chromatin remodeling hypothesis: restoring disrupted gene expression patterns toward a homeostatic set point rather than uniformly stimulating or inhibiting.
The 2002 Khavinson/Lezhava study, indexed in Bulletin of Experimental Biology and Medicine, treated lymphocytes from elderly donors with Livagen in vitro. The results showed: (1) activation of ribosomal genes, indicative of restored nucleolar activity and protein synthesis capacity; (2) decondensation of pericentromeric structural heterochromatin, the most condensed chromatin compartment; (3) release of genes repressed due to age-related condensation of euchromatic regions. The authors concluded that Livagen causes de-heterochromatinization of chromatin realized via modification of heterochromatin and heterochromatinized chromosomal regions in cells from old people.
The 2006 Lezhava et al. companion study in donors aged 75 to 88 years compared Epitalon, Livagen, and Vilon on chromatin parameters. Livagen and Epitalon both produced decondensation of pericentromeric structural heterochromatin of chromosomes 1 and 9, while Vilon did not affect these pericentromeric regions. All three peptides activated facultative heterochromatin. This differential pericentromeric effect distinguishes Livagen from Vilon and aligns it with Epitalon in terms of chromatin targeting breadth.
The human lymphocyte experiments are the most human-proximate data in the Livagen profile. They establish that the chromatin remodeling effects, observed in the same experimental system for multiple Khavinson bioregulators, extend to Livagen specifically and include both structural and functional heterochromatin modification. These remain in vitro observations; the translational significance depends on whether lymphocyte chromatin aging is a disease driver or a correlate.
The chromatin activation findings are mechanistically specific, use human biological material, and have been reproduced in multiple publications from the Lezhava group (Georgia) in addition to the Khavinson group. The differential pericentromeric effects between Livagen and Vilon in the same experimental system support genuine sequence-specific activity. The limitation is that all results are from lymphocytes in culture, not from in vivo human studies, and no clinical outcome has been measured in any study.
Livagen inhibited enkephalin-degrading enzymes in human serum in vitro with an IC50 of 20 micromolar. Epitalon's IC50 was 500 micromolar for the same enzyme system. Livagen outperformed three established peptidase inhibitors used as comparators: puromycin, leupeptin, and D-PAM. Dose-response curves were plotted for both peptides.
Neither Livagen nor Epitalon interacted with mu or delta opioid receptors in a radioreceptor assay using tritium-labeled D-Ala2, D-Leu5-enkephalin and rat brain membrane fractions. This dissociation between enkephalinase inhibition and opioid receptor binding confirms that the mechanism is enzyme inhibition rather than receptor agonism. Livagen does not act as an opioid; it prevents degradation of endogenous opioids without mimicking them.
The 25-fold potency advantage of Livagen over Epitalon (IC50 20 versus 500 micromolar) and the superiority over established inhibitors is a mechanistically striking finding. The study was conducted at the Mental Health Research Center in Moscow, an institution external to the St. Petersburg Khavinson group, providing the only truly independent institutional validation in the Livagen literature.
The physiological significance depends on whether Livagen achieves serum concentrations approaching 20 micromolar following any administration route. No pharmacokinetic data exist to evaluate this. If oral Livagen is not hydrolyzed by intestinal peptidases (as documented by Timofeeva 2005), systemic bioavailability could in principle be sufficient for enkephalinase inhibition, but this has not been measured.
The enkephalin enzyme inhibition finding is the most analytically rigorous piece of data in the Livagen profile: quantified IC50, dose-response curves, comparison to established inhibitors, and confirmation of opioid receptor non-interaction, conducted at an independent Moscow institution. The mechanistic significance is real. The gap between IC50 in vitro and achievable serum concentrations in vivo is not characterized, limiting the ability to predict whether this mechanism produces meaningful physiological effects at any dose.
The 2005 Timofeeva et al. study established a foundational pharmacological property of Livagen: it is weakly hydrolyzed by small intestinal peptide hydrolases in vitro. After 2 weeks of oral Livagen administration in rats, digestive enzyme activity in young animals decreased while in old animals it increased. In old rats, the activity of enzymes after Livagen administration approached the level seen in young control animals. This bidirectional, age-dependent normalization is a hallmark of the Khavinson bioregulator effect pattern and consistent with a chromatin remodeling mechanism restoring physiologically appropriate gene expression rather than uniformly stimulating or inhibiting targets.
The 2020 Kuznik et al. review (Advances in Gerontology) summarized experimental liver pathology data, reporting that KEDA (Livagen) demonstrated high efficiency in liver fibrosis, acute hepatitis, and chronic hepatitis models in animals and in vitro. Livagen and the Ventvil polypeptide complex had concordant effects: normalized immune and antioxidant status and restored liver function during hepatitis. The maximal hepato- and immunoprotective effect was observed in the aging context, consistent with the aging-specific chromatin remodeling hypothesis. A key cited finding was that KEDA influences the rheological properties of blood in viral hepatitis A patients, slowing clotting and inhibiting fibrinolysis, though whether this represents a direct in vivo effect or a cell culture observation is not fully clear from the review format.
The oral bioavailability inference from the Timofeeva study is notable: if Livagen survives intestinal peptidases and normalizes GI enzyme activity in aged rats after 2 weeks of oral dosing, it must either be absorbed systemically and act on gene expression in intestinal cells, or function locally within the gut lumen on mucosal cells. The former would suggest meaningful oral bioavailability for a tetrapeptide, which is unusual.
The hepatoprotective and GI data are the evidence base for Livagen's liver-targeted branding. The aging-specific GI enzyme normalization is internally coherent with the chromatin mechanism. The liver protection data in experimental hepatitis models is meaningful preclinically. All data are from rodents or cell cultures. The hepatitis A blood rheology claim involves human material (viral hepatitis patients) but appears in a review rather than a primary clinical study, and the study parameters are not characterized. No controlled human liver study has been published.
The 2014 Dzhokhadze et al. HCM study examined lymphocytes from hypertrophic cardiomyopathy patients and their relatives. Livagen, both alone and in combination with cobalt ions, increased the frequency of large-sized NOR activity and influenced the associative activity of acrocentric chromosomes. These changes were interpreted as evidence that chromatin remodeling by Livagen may improve NOR activity and nucleolar function in lymphocytes carrying the genomic features associated with HCM. The findings suggest that Livagen's chromatin effects in aging lymphocytes extend to disease-associated genomic instability patterns.
The 2014 genomic instability study in atherosclerosis patients examined chromosome aberration rates and NOR activity in lymphocytes from atherosclerosis patients. Livagen treatment in this cell culture model reduced markers of chromosomal instability, suggesting potential relevance to vascular disease contexts where genomic stress in immune cells has been documented.
These studies are conducted entirely in cell culture using lymphocytes from patients with defined cardiovascular conditions. They do not demonstrate any clinical cardiovascular benefit of Livagen in these patients. They extend the chromatin remodeling finding from the general aging lymphocyte context to disease-specific populations, which is mechanistically informative but not clinically definitive. Both studies come from the Lezhava group at Tbilisi State University, Georgia.
These cardiovascular chromatin studies are a mechanistic extension of the aging lymphocyte work into disease-relevant populations. NOR activity and acrocentric chromosome associations in HCM patient lymphocytes are plausible disease-relevant endpoints given evidence that immune cell genomic stability plays roles in cardiovascular pathology. The clinical significance is speculative. The findings do not establish that Livagen produces any benefit in HCM or atherosclerosis patients. They establish that Livagen's chromatin effects are observable in these cell populations.
The 2022 Lezhava et al. study in International Journal of Peptide Research and Therapeutics compared Livagen and Epitalon in combination with heavy metal ions (cobalt, nickel, zinc) in aged human lymphocytes. The study found that Livagen and Epitalon demonstrated anti-mutagenic protective effects in both young and old age groups, reducing the metal ions' ability to induce chromosomal aberrations. Livagen was particularly effective at protecting pericentromeric and telomeric heterochromatin from metal-induced damage. The 2022 publication is in an indexed English-language journal, representing the most recent Livagen chromatin study identified.
The 2023 Georgian Medical News study continued this comparative series, examining Livagen alongside other Khavinson bioregulators on aged chromatin parameters. The researchers characterized what they called epigenetic modification patterns of old chromatin, reporting that Livagen produced chromatin activation consistent with earlier publications.
The anti-mutagenic protection finding adds a new dimension to the Livagen profile: beyond restoring gene expression in aging cells, Livagen may reduce the susceptibility of aged chromatin to mutagenic damage. This could be relevant in the context of environmental heavy metal exposure in aging populations. The mechanism proposed is that structural stabilization of chromatin via deheterochromatinization prevents the formation of aberrant DNA structures susceptible to metal-induced damage.
The mutagenic protection finding in aged lymphocytes is mechanistically interesting as an extension of the deheterochromatinization work into genotoxic protection. Protecting aged chromatin from heavy metal mutagenicity is a specific and testable hypothesis. The 2022 IJPRT publication is the most externally validated recent Livagen finding. All results remain in vitro in human cell cultures, with no clinical translation established.
Khavinson bioregulator peptide.
No human pharmacokinetic or dose-finding study has been published for Livagen. The documented resistance of Livagen to intestinal peptidase hydrolysis is pharmacologically unusual for a tetrapeptide and suggests potentially greater oral stability than predicted from peptide chemistry alone, but systemic bioavailability remains unmeasured. Commercial research vendor protocols of 200 to 1000 mcg daily are extrapolated from the Khavinson bioregulator class convention rather than from any Livagen-specific PK or dose-finding data. Unlike Pancragen, Cardiogen, and Vesugen, Livagen does not appear to be sold as a commercial supplement by the St. Petersburg Institute, suggesting the Institute itself does not consider the evidence sufficient for supplement promotion.
Within the Khavinson bioregulator family, Livagen is notable for having the most mechanistically specific in vitro findings (particularly the enkephalin enzyme IC50) while having the weakest clinical evidence (no human patient data of any kind, compared to Pancragen's n=33 DM2 study and Vesugen's observational cardiovascular series). Livagen's chromatin remodeling profile is similar to Epithalon but distinct in its pericentromeric targeting profile. The KED-shared core sequence with Vesugen and Pancragen raises the question of overlapping mechanisms across these liver, vascular, and pancreatic bioregulators; the C-terminal alanine of Livagen versus aspartic acid and tryptophan extensions of the others may determine tissue specificity but this has not been directly tested in comparative biodistribution studies. Of the entire Khavinson bioregulator family, Epithalon has attracted the most Western scientific interest and has the most extensive anti-aging literature, while Livagen remains primarily of mechanistic research interest in the chromatin remodeling and opioid-modulation contexts.
No human pharmacokinetic or safety data have been published for Livagen. No human clinical exposure is documented. The following reflects in vitro and animal model observations.
The 2005 Timofeeva et al. study documented that Livagen is weakly hydrolyzed by intestinal peptidases in vitro, with small intestinal peptide hydrolases failing to hydrolyze Livagen even to a small extent. This resistance to intestinal degradation is relevant both to oral bioavailability (if KEDA survives digestion, it may be more systematically bioavailable than typical tetrapeptides) and to safety (unhydrolyzed peptides may accumulate in the gut lumen and produce local effects not attributable to systemic distribution). No organ toxicity data from any Livagen animal study have been reported.
The enkephalin enzyme inhibition finding has an implicit safety consideration: at pharmacologically active doses in vivo, Livagen would be expected to raise endogenous enkephalin levels by reducing their degradation. Enkephalins at elevated levels produce analgesic, potentially anxiolytic, and cardiovascular modulating effects. In the context of normal physiology, this is generally benign. In patients on opioid analgesics, significant elevation of endogenous enkephalin levels could theoretically alter the pharmacological environment. This interaction has not been studied.
No serious adverse effects have been reported in any published Livagen animal study. No chromosomal damage, toxicity, or organ-level pathology is described in the hepatoprotective rodent studies. The compound is composed entirely of amino acids present in normal human physiology. Tetrapeptides are generally expected to be rapidly metabolized; Livagen's documented resistance to intestinal peptidases is an exception that would need to be characterized for other tissue compartments.
Livagen has the smallest published human evidence base of the Khavinson bioregulators reviewed in this series, and yet it has two of the most mechanistically specific findings: the indexed chromatin deheterochromatinization study in human lymphocytes from elderly donors, and the enkephalin-degrading enzyme inhibition study with IC50 of 20 micromolar, conducted at an independent Moscow institution, outperforming established peptidase inhibitors.
The chromatin findings establish that Livagen does something real and specific to aging human chromatin in vitro. The pericentromeric heterochromatin decondensation that distinguishes Livagen from Vilon in the same experimental system supports sequence-specific rather than nonspecific activity. Twenty years of follow-up publications from the Lezhava group in Georgia have repeatedly confirmed and extended these findings, with the 2022 International Journal of Peptide Research and Therapeutics paper providing the most recent indexed evidence.
The enkephalin enzyme inhibition finding is arguably the most pharmacologically precise datum in the Khavinson bioregulator literature. An IC50 of 20 micromolar measured against human serum enzymes, compared at the same concentration against puromycin, leupeptin, and D-PAM, with confirmed absence of opioid receptor binding, is a clean mechanistic finding from an independent institution. Its clinical relevance depends entirely on whether Livagen achieves micromolar serum concentrations following any route of administration, which is unknown.
The hepatoprotective and GI data in rodents are internally coherent with the chromatin model and suggest Livagen has tissue effects in liver and intestinal biology that make its liver-targeted nomenclature appropriate. But like all other Livagen findings, they are preclinical.
Livagen's profile is defined by mechanistic specificity in in vitro systems combined with a complete absence of human clinical data. If the enkephalinase inhibition translates to in vivo significance, Livagen would be an endogenous opioid system modulator without opioid receptor activity, an unusual pharmacological class with potential relevance to pain, cardiovascular protection, and immune modulation. That hypothesis has not been tested clinically anywhere.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use